Researchers at the University of Oulu in Finland have discovered novel genes and mechanisms that can explain how a genomic variant in a single nucleotide polymorphism (SNP) rs11672691 influences prostate cancer aggressiveness. Their findings also suggest ways to improve risk stratification and clinical treatment for advanced prostate cancer. The study is published in the journal Cell.
Three billion base pairs in the human genome are nearly identical between any two individuals. Nevertheless, genome sequence variation such as single nucleotide polymorphism does occur in the population, and may have profound effects on an individual’s risk of developing various diseases, including prostate cancer. “How human genomic variants cause disease and its progression is in general one of the most compelling puzzles and questions in medicine,” says Academy Research Fellow Gong-Hong Wei at Biocenter Oulu in the University of Oulu.
Novel genes and fundamental mechanisms
The single nucleotide polymorphism (SNP) rs11672691 at the region of chromosome 19q13 has been found associated with aggressive prostate cancer, but how this genomic variant accounts for this association had not yet been uncovered. Using genetic, genomic, molecular and bioinformatic analysis, Gong-Hong Wei and his multinational collaborators confirmed the association in a large cohort of prostate cancer
Article originally posted at